Boston Scientific falls 4.2% as valuation sinks to five-year lows

Boston Scientific shares have lost more than half their value over the past year, pushing its price-to-earnings ratio to 18.8x — a fraction of its five-year median of 67.9x.

Boston Scientific Corp.'s 4.2% decline to $44.95 on Wednesday extended a selloff that has erased 52.9% of the medical device maker's market value year-to-date, pushing its price-to-earnings ratio to 18.8x — well below its five-year median of 67.9x. The stock now trades within 1% of its 52-week low of $44.79.

GuruFocus data shows the stock trades 57.3% below its GF Value of $105.30, a proprietary intrinsic value measure, classifying BSX as "significantly undervalued." The company's GF Score of 75 out of 100 reflects above-average financial health, with top marks in profitability (9 out of 10) and growth (10 out of 10) but weak scores in valuation (2 out of 10) and momentum (1 out of 10).

The selloff comes despite improving fundamentals. Analysts project third-quarter earnings per share of 83 cents, up 10.7% from a year earlier, on revenue of $5.39 billion, according to Zacks Consensus Estimates. For the full year, Boston Scientific is expected to report earnings of $3.36 per share on revenue of $21.61 billion, representing growth of 9.8% and 7.7%, respectively. The forward P/E of 13.3x represents a discount to the medical products industry average of 17.5x and to rival Medtronic's forward multiple of about 16x.

Insiders have purchased $600,000 worth of shares over the past three months with no selling activity, a signal that management sees value at current levels. The stock's PEG ratio of 0.9 — below the industry average of 1.59 — suggests the market may be underestimating Boston Scientific's earnings growth potential. However, the Zacks Rank of #4 (Sell) indicates near-term headwinds persist, and the momentum score of 1 out of 10 suggests further downside cannot be ruled out.

A Valuation Disconnect

The gap between Boston Scientific's operational performance and its stock price highlights a potential disconnect. The company earns a growth score of 10 out of 10 from GuruFocus, reflecting strong revenue and earnings expansion, yet its valuation score of 2 out of 10 signals deep market pessimism. The 52-week range of $44.79 to $109.50 illustrates the magnitude of the decline from a stock that traded above $100 as recently as mid-2025. By comparison, Medtronic has fallen 18% over the same period, making Boston Scientific's 55.8% decline over the past year an outlier among large-cap medical device peers.

What's Next for BSX

With the next earnings report expected in late July, investors will watch for any revision to full-year guidance. The consensus EPS estimate has edged 0.51% lower over the past 30 days, per Zacks, suggesting analysts are tempering expectations. Boston Scientific's ability to maintain its growth trajectory — with revenue projected to rise 7.7% this year — will determine whether the current valuation floor holds or gives way to further declines. At 13.3x forward earnings, the stock already prices in a significant slowdown, leaving room for a recovery if the company delivers on its growth targets.

This article is for informational purposes only and does not constitute investment advice.